Dark

Check out our Dark Pool Levels

CERC
Cerecor Inc.
stock NASDAQ

Inactive

Aug 25, 2021

2.93USD-1.678%(-0.05)268,049

Pre-market

0.00USD-100.000%(-2.98)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Aug 26, 2021

07:37AM EDT Avalo Therapeutics, Inc. Announces Corporate Name Change from Cerecor Inc. Benzinga

07:30AM EDT Avalo Therapeutics, Inc. Announces Corporate Name Change from GlobeNewswire Inc

Aug 6, 2021

08:55AM EDT Clinicaltrials.gov Site Shows Cerecor-Sponsored Study 'A Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of CERC-006 in Adults With Complex Lymphatic Malformations' Not Yet Recruiting Benzinga

Aug 2, 2021

04:06PM EDT Cerecor Q2 EPS $(0.18), Same YoY, Sales $3.35M Up From $1.34M YoY Benzinga

04:01PM EDT Cerecor Reports Second Quarter 2021 Financial Results and Provides GlobeNewswire Inc

07:35AM EDT Cerecor Announces Drawdown Of $10M Tranche Under Its Debt Financing Agreement With Horizon Technology Finance Benzinga

07:30AM EDT Cerecor Announces Drawdown of $10 Million Tranche under its Debt GlobeNewswire Inc

Jul 27, 2021

11:13AM EDT The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts Benzinga

06:16AM EDT Cerecor's Crohn's Disease Candidate Shows Encouraging Response In Pretreated Patients Benzinga

Jul 26, 2021

04:02PM EDT Cerecor Announced Initial Phase 1b Results For CERC-002 In Moderate To Severe Crohn's Disease Patients Benzinga

04:01PM EDT Cerecor Announces Positive Initial Phase 1b Results for CERC-002 GlobeNewswire Inc

Jul 2, 2021

04:26PM EDT Cerecor Says Entered Into Controlled Equity Offering Sales Agreement; Says Pursuant To Sales Agreement Co. May Issue, Sell Common Stock Having Offering Price Of Up To $50M Benzinga

Jun 23, 2021

07:32AM EDT Cerecor Licenses Immune Checkpoint Program From Sanford Burnham Prebys Further Expanding Pipeline Of Immunology And Immuno-oncology Targets Benzinga

07:30AM EDT Cerecor Licenses Immune Checkpoint Program from Sanford Burnham GlobeNewswire Inc

Jun 7, 2021

07:07AM EDT Cerecor Enters Into $35M Debt Financing Agreement With Horizon Technology Finance Benzinga

07:00AM EDT -- An initial tranche of $20 million drawn at the loan closing -- Funds ongoing clinical development of key investigational product candidates -- Financing provides flexibility and extends runway through multiple clinical catalysts expected in 2021 GlobeNewswire Inc

Jun 4, 2021

10:03AM EDT Benzinga's Top Ratings Upgrades, Downgrades For June 4, 2021 Benzinga

08:10AM EDT Cantor Fitzgerald Initiates Coverage On Cerecor with Overweight Rating, Announces Price Target of $7 Benzinga

May 17, 2021

07:00AM EDT Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases, today announced that members of its senior management team will participate in three upcoming virtual investor conferences. GlobeNewswire Inc

May 13, 2021

07:03AM EDT Cerecor Q1 EPS $(0.32) Up From $(0.36) YoY Benzinga

07:00AM EDT Cerecor Reports First Quarter 2021 Financial Results and Provides GlobeNewswire Inc

May 11, 2021

09:15AM EDT Cerecor Shares Gain After FDA Fast Track Review Tag For CERC-002 In Hospitalized COVID-19 Patients Benzinga

07:54AM EDT The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings Benzinga

07:19AM EDT Biopharmaceutical company Cerecor Inc. (CERC) announced Tuesday that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CERC-002 for treatment of hospitalized patients with COVID-19. RTTNews

07:09AM EDT Cerecor: FDA Grants Fast Track Designation To CERC-002 For Hospitalized Patients With COVID-19 RTTNews

07:03AM EDT FDA Grants Fast Track Designation To Cerecor's CERC-002 For Treatment Of Hospitalized Patients With COVID-19 Benzinga

07:00AM EDT FDA Grants Fast Track Designation to CERC-002 for Treatment of GlobeNewswire Inc

May 5, 2021

07:06AM EDT Cerecor Doses First Patient In Phase 1b Proof-of-Concept Clinical Trial Of CERC-007 For Treatment Of Adult Onset Still's Disease Benzinga

07:00AM EDT -- Initial data anticipated in the third quarter of 2021 -- Top-line data from the ongoing Phase 1b proof of concept clinical trial in relapsed or refractory multiple myeloma patients anticipated in the second half of 2021 GlobeNewswire Inc

Apr 21, 2021

01:59PM EDT Benzinga's Top Ratings Upgrades, Downgrades For April 21, 2021 Benzinga

09:52AM EDT Maxim Group Upgrades Cerecor to Buy, Announces $7 Price Target Benzinga

Apr 20, 2021

01:33PM EDT Cerecor shares were trading higher after Jefferies initiated coverage on the stock with a Buy rating and a price target of $4 per share. Benzinga

10:04AM EDT Benzinga's Top Ratings Upgrades, Downgrades For April 20, 2021 Benzinga

08:18AM EDT Jefferies Initiates Coverage On Cerecor with Buy Rating, Announces Price Target of $4 Benzinga

Mar 29, 2021

09:39AM EDT Cerecor Inks New Global License Agreement With Kyowa Kirin For CERC-002 Benzinga

07:03AM EDT Cerecor Announces New Worldwide License Agreement with Kyowa Kirin for Anti-LIGHT Antibody CERC-002; No Financial Terms Disclosed Benzinga

07:00AM EDT -- Expanded agreement for exclusive, world-wide rights to develop, manufacture and commercialize CERC-002 for all indications including severe pediatric onset inflammatory bowel disease and ARDS (including COVID-19 ARDS) -- Kyowa Kirin Co. has an option to retain the rights for all indications in Japan GlobeNewswire Inc

Mar 9, 2021

09:17AM EST The Daily Biotech Pulse: Regulatory Setback For Acadia, Lilly Forges Diabetes Antibody Treatment Collaboration, Aytu's Positive COVID-19 Data Benzinga

Mar 8, 2021

05:20PM EST Cerecor S-3 Shows Registration For $150M Mixed Securities Shelf Offering Benzinga

04:04PM EST Cerecor Reports FY20 Sales $6.7M Down From $6.75M YoY Benzinga

04:01PM EST ? Announced CERC-002 significantly reduced respiratory failure and mortality in Phase 2 clinical trial in patients hospitalized with COVID-19 ARDS ? Improved financial position with $18.9M of cash on hand as of December 31, 2020 and $37.6M of net proceeds raised in January 2021 ? Poised to deliver significant number of clinical and regulatory catalysts in 2021 GlobeNewswire Inc

Mar 4, 2021

07:00AM EST Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases, today announced that Michael F. Cola, President and Chief Executive Officer, will present at two upcoming virtual conferences. GlobeNewswire Inc

Mar 2, 2021

08:48AM EST Cerecor Shares Are Trading Higher On Positive CERC-002 Efficacy Data In COVID-19 Study Benzinga

08:01AM EST The Daily Biotech Pulse: Roxadustat Delay For FibroGen, AstraZeneca, Decision Day For KemPharm, NanoViricides Jumps On COVID-19 Drug Data Benzinga

07:13AM EST Cerecor Announces Final Efficacy Data From Phase 2 Trial Of CERC-002; Says CERC-002 Was Statistically Significant In Reducing Respiratory Failure And Mortality At Day 28 In Patients Hospitalized With COVID-19 Associated Pneumonia Benzinga

07:00AM EST Cerecor Announces CERC-002 Significantly Reduced Respiratory GlobeNewswire Inc

Mar 1, 2021

07:18AM EST Cerecor Appoints Schond L. Greenway as Chief Financial Officer Benzinga

07:09AM EST Cerecor Appoints Schond Greenway As CFO RTTNews

07:00AM EST Cerecor Appoints Schond L. Greenway as Chief Financial Officer GlobeNewswire Inc

Feb 23, 2021

07:25AM EST The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts Benzinga

Feb 17, 2021

07:27AM EST The Daily Biotech Pulse: Novartis Funding For Gene Therapy Research, Priority Review For Amgen Cancer Drug, Pfizer-BioNTech Vaccine Supply Deal Benzinga

Feb 2, 2021

09:14AM EST Cerecor's CERC-803 Nabs US Orphan Drug Tag In Rare Immunodeficiency Disorder Benzinga

07:19AM EST Cerecor Reports Fast Track Designation For CERC-803 For Treatment Of Leukocyte Adhesion Deficiency Type II Benzinga

07:00AM EST Cerecor Announces Fast Track Designation for CERC-803 for the GlobeNewswire Inc

Jan 20, 2021

07:06AM EST Cerecor Announces Proceeds From Option To Purchase Additional Shares Of Common Stock, Bringing Public Offering Proceeds To $40.7M Benzinga

07:00AM EST Cerecor Announces Proceeds from Option to Purchase Additional GlobeNewswire Inc

Jan 12, 2021

04:01PM EST Cerecor Inc. Announces Closing of $36.4 Million Public Offering of GlobeNewswire Inc

Jan 8, 2021

07:25AM EST The Daily Biotech Pulse: Sarepta Gene Therapy Study Readout, Novavax Vaccine Supply Deal, 2 IPOs Benzinga

Jan 7, 2021

10:03PM EST Cerecor Inc. Announces Pricing of $36.4 Million Public Offering of GlobeNewswire Inc

04:01PM EST Cerecor Inc. Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants; No Terms Disclosed Benzinga

04:01PM EST Cerecor Inc. Announces Proposed Public Offering of Common Stock GlobeNewswire Inc

Jan 5, 2021

08:39AM EST The Daily Biotech Pulse: Moderna Coronavirus Vaccine Receives Third Regulatory Nod, Gritstone Rallies On Hedge Fund Stake, aTyr's COVID-19 Drug Data Benzinga

07:02AM EST UPDATE: Cerecor Says 'COVID-19 ARDS patients treated with a single dose of the anti-LIGHT monoclonal antibody CERC-002 demonstrated robust improvement in the primary endpoint' Compared To Placebo Benzinga

07:01AM EST Cerecor Announces Proof Of Concept Data For CERC-002 LIGHT-Neutralizing Antibody, In Patients Hospitalized With COVID-19 ARDS Benzinga

07:00AM EST Cerecor Announces Successful Proof of Concept Data for CERC-002, a GlobeNewswire Inc

Dec 22, 2020

01:00PM EST Cerecor Reports FDA Accepted Investigational New Drug Application for CERC-007 For Treatment Of Still's Disease Benzinga

01:00PM EST Cerecor Announces FDA Acceptance of Investigational New Drug GlobeNewswire Inc

Dec 16, 2020

07:02AM EST Cerecor Announces First Patient Dosed in a Phase 1b Clinical Trial of CERC-007 for the Treatment of Relapsed or Refractory Multiple Myeloma Benzinga

07:01AM EST Cerecor Announces First Patient Dosed in a Phase 1b Clinical Trial GlobeNewswire Inc

Dec 8, 2020

07:18AM EST Cerecor: FDA Accepts IND Application For CERC-007 For Treatment Of Relapsed Or Refractory Multiple Myeloma RTTNews

07:02AM EST Cerecor Announces FDA Acceptance Of Investigational New Drug Application For CERC-007 For Treatment Of Relapsed Or Refractory Multiple Myeloma Benzinga

07:00AM EST Cerecor Announces FDA Acceptance of Investigational New Drug GlobeNewswire Inc

Dec 1, 2020

07:20AM EST Cerecor Announces FDA Acceptance Of IND Application For CERC-803 To Treat Leukocyte Adhesion Deficiency Type II RTTNews

07:00AM EST Cerecor Announces FDA Acceptance of Investigational New Drug GlobeNewswire Inc

Nov 17, 2020

07:12AM EST Cerecor To Partner With Frontiers CDG Consortium On Pivotal Trial Of CERC-801 For PGM1-CDG Treatment RTTNews

07:03AM EST Cerecor to Collaborate with Frontiers CDG Consortium on Pivotal Trial of CERC-801 for the Treatment of PGM1-CDG Benzinga

07:00AM EST Cerecor to Collaborate with Frontiers CDG Consortium on Pivotal GlobeNewswire Inc

Nov 9, 2020

04:16PM EST Cerecor Q3 EPS $(0.17) Down From $(0.07) YoY, Sales $1.11M Down From $5.61M YoY Benzinga

04:01PM EST On track to complete clinical trial for CERC-002 in cytokine storm-induced COVID-19 ARDS by year end GlobeNewswire Inc

Oct 12, 2020

07:00AM EDT Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced the appointment of Gilla Kaplan, Ph.D., to the Board of Directors. Dr. Kaplan brings with her over 30 years of academic and industry experience. GlobeNewswire Inc

Aug 26, 2020

07:13AM EDT Cerecor Resumes Phase 1b Clinical Trial of CERC-002 for the Treatment of Severe Pediatric Onset Crohn's Disease Benzinga

07:04AM EDT Cerecor Resumes Phase 1b Clinical Study Of CERC-002 In Anti-TNF Refractory Adult Crohn's Patients RTTNews

07:00AM EDT Cerecor Resumes Phase 1b Clinical Trial of CERC-002 for the GlobeNewswire Inc

Aug 13, 2020

07:27AM EDT Cerecor Announces Peer-Reviewed Publication Highlighting 'the Role of the Inflammatory Cytokine, LIGHT, in COVID-19 ARDS' Benzinga

07:00AM EDT Cerecor Announces Peer-Reviewed Publication Highlighting the Role GlobeNewswire Inc

Aug 6, 2020

10:40AM EDT Cerecor Earlier Reported Q2 EPS $(0.19) Down From $(0.11) YoY, Sales $1.34M Down From $4.45M YoY Benzinga

07:01AM EDT -Generated net proceeds of $48 million from equity offering and disposition of Aytu shares to support pipeline advancement GlobeNewswire Inc

Aug 5, 2020

07:01AM EDT Cerecor Inc. (NASDAQ: CERC), a leading biopharmaceutical company focused on the development and commercialization of treatments for rare pediatric and orphan diseases, today announced that Michael F. Cola, President and Chief Executive Officer, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11, 2020 at 8:00 a.m. EDT. GlobeNewswire Inc

Aug 4, 2020

09:51AM EDT Cerecor shares are trading higher after the company announced it has received rare pediatric disease designation by the FDA for CERC-006 for the treatment of lymphatic malformations. Benzinga

07:24AM EDT Cerecor Receives Rare Pediatric Disease Designation For CERC-006 In Lymphatic Malformations Benzinga

07:00AM EDT Cerecor Inc. (NASDAQ: CERC), a leading biopharmaceutical company in the development and commercialization of treatments for rare pediatric and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease Designation (RPDD) to CERC-006, a dual inhibitor of mTOR complexes 1 and 2 for the treatment of lymphatic malformations (LM). GlobeNewswire Inc

Aug 3, 2020

07:19AM EDT Cerecor Gets Orphan Drug Designation For CERC-006 In Lymphatic Malformations RTTNews

07:03AM EDT Cerecor Receives Orphan Drug Designation For CERC-006 In Lymphatic Malformations Benzinga

07:02AM EDT Cerecor Inc. (NASDAQ: CERC), a leading biopharmaceutical company in the development and commercialization of treatments for rare pediatric and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to CERC-006, a dual inhibitor of mTOR complexes 1 and 2 for the treatment of lymphatic malformations (LM). GlobeNewswire Inc

Jul 21, 2020

07:10AM EDT Cerecor Says First Patient Enrolled In Multicenter Proof-of-Concept Study Evaluating CERC-002 For COVID-19 ARDS RTTNews

07:06AM EDT Cerecor Announces First Patient Enrolled In Multicenter Proof-Of-Concept Study Evaluating CERC-002 For COVID-19 ARDS Benzinga

07:00AM EDT Cerecor Announces First Patient Enrolled in Multicenter GlobeNewswire Inc

Share